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Abstract
Background: The Bangkok Tenofovir Study was launched in 2005 to determine if pre-exposure prophylaxis with tenofovir
will reduce the risk of HIV infection among injecting drug users (IDUs). We describe recruitment, screening, enrollment, and
baseline characteristics of study participants and contrast risk behavior of Tenofovir Study participants with participants in
the 1999–2003 AIDSVAX B/E Vaccine Trial.
Methods: The Bangkok Tenofovir Study is an ongoing, phase-3, randomized, double-blind, placebo-controlled, HIV pre-
exposure prophylaxis trial of daily oral tenofovir. The Tenofovir Study and the Vaccine Trial were conducted among IDUs at
17 drug-treatment clinics in Bangkok. Tenofovir Study sample size was based on HIV incidence in the Vaccine Trial.
Standardized questionnaires were used to collect demographic, risk behavior, and incarceration data. The Tenofovir Study is
registered with ClinicalTrials.gov, number-NCT00119106.
Results: From June 2005 through July 2010, 4094 IDUs were screened and 2413 enrolled in the Bangkok Tenofovir Study.
The median age of enrolled participants was 31 years (range, 20–59), 80% were male, and 63% reported they injected drugs
during the 3 months before enrollment. Among those who injected, 53% injected methamphetamine, 37% midazolam, and
35% heroin. Tenofovir Study participants were less likely to inject drugs, inject daily, or share needles (all, p,0.001) than
Vaccine Trial participants.
Discussion: The Bangkok Tenofovir Study has been successfully launched and is fully enrolled. Study participants are
significantly less likely to report injecting drugs and sharing needles than participants in the 1999–2003 AIDSVAX B/E
Vaccine Trial suggesting HIV incidence will be lower than expected. In response, the Bangkok Tenofovir Study enrollment
was increased from 1600 to 2400 and the study design was changed from a defined 1-year follow-up period to an endpoint-
driven design. Trial results demonstrating whether or not daily oral tenofovir reduces the risk of HIV infection among IDUs
are expected in 2012.
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Introduction
HIV spread rapidly among injecting drug users (IDUs) in
Bangkok in the late 1980s [1] and HIV prevalence has remained
high, 30% to 50% [2,3]. Safe and effective tools to prevent HIV
infection among IDUs are urgently needed. Use of antiretroviral
drugs before HIV exposure (pre-exposure prophylaxis) may
protect people at high risk of HIV from infection and provide a
new tool to reduce HIV transmission.
The Bangkok Tenofovir Study is an ongoing phase-3,
randomized, double-blind, placebo-controlled, endpoint-driven
HIV prevention trial that aims to determine if daily oral Tenofovir
Disoproxil Fumarate (tenofovir) will reduce HIV transmission
among IDUs. Tenofovir, a nucleotide reverse transcriptase
inhibitor, is a potent antiretroviral with a long half-life allowing
once-daily dosing [4–7]. Data from clinical trials among people
infected with HIV have shown that tenofovir has a good safety
profile [8,9], a low potential to select for tenofovir resistance
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e25127[10,11], and co-administration of tenofovir with methadone and/
or oral contraceptives does not alter the pharmacokinetics or
pharmacodynamics of these drugs [12,13]. Tenofovir was licensed
for the treatment of HIV infection by the US Food and Drug
Administration in 2001 and the Thailand Food and Drug
Administration in 2006.
Several lines of evidence suggest that pre-exposure prophylaxis
with tenofovir will reduce HIV transmission among IDUs. Studies
of macaques have shown that tenofovir can prevent or delay
infection with simian immunodeficiency virus and humanized
derivatives called SHIV [14–17] and the use of antiretroviral drugs
reduces the risk that HIV-infected pregnant women will transmit
HIV to their newborns [18] and that health care workers will
become infected following occupational exposures to HIV [19,20].
Following consultations with IDUs and representatives of
organizations working with communities at risk for HIV infection,
we began preparations for an HIV pre-exposure prophylaxis trial
in 2004 [21]. The findings of two longitudinal studies conducted
among IDUs in Bangkok informed the design of the study. The
first was a preparatory cohort study [22] that enrolled 1209 IDUs
at drug-treatment clinics managed by the Bangkok Metropolitan
Administration (BMA), the city government of Bangkok, during
1995–1996 and followed them for 3 years. The second study was
the 1999–2003 AIDSVAX B/E Vaccine Trial [23] conducted
among 2546 IDUs in the same BMA drug-treatment clinics. The
vaccine did not prevent HIV infection, but IDUs showed a
continued willingness to participate in research and 90%
completed the study. HIV incidence remained stable during
follow-up at 3.4 per 100 person-years.
Based on community interest in promising HIV prevention
interventions, ongoing high HIV incidence among IDUs [23], and
evidence suggesting pre-exposure prophylaxis with tenofovir would
prevent HIV infection [14–20], a protocol to evaluate tenofovir
among IDUs was developed and submitted for regulatory review.
Regulatory approvals were obtained in May 2005 and the Bangkok
Tenofovir Study was launched in June 2005.
Since the study began several other pre-exposure prophylaxis
trials have provided results that support the rationale for the
Bangkok Tenofovir Study. A trial among women in South Africa
found use of tenofovir vaginal gel reduced HIV acquisition by
39% [24] and a trial among men who have sex with men found
use of daily oral truvada (tenofovir+emtricitabine) reduced HIV
incidence by 44% [25]. Although a trial comparing daily oral
truvada to placebo among women in several African countries was
stopped in 2010 because interim data showed that it was unlikely
the study would demonstrate lower HIV infection rates among
women receiving truvada [26], a trial among heterosexual men
and women in Botswana found that participants randomized to
receive daily truvada were 63% less likely to become HIV infected
than participants receiving placebo [27] and a trial among
heterosexual HIV serodiscordant couples in Kenya and Uganda
found that daily tenofovir reduced HIV acquisition 62% and daily
truvada 73% compared to placebo [28].
Overall, these studies provide evidence that pre-exposure
prophylaxis with tenofovir or truvada is safe and can reduce the
risk of sexual transmission of HIV among heterosexual couples
and men who have sex with men. The results do not provide
information about the efficacy of tenofovir or truvada to prevent
parenteral transmission of HIV among IDUs. In order to
determine if daily oral tenofovir can reduce the risk of HIV
infection among IDUs, we are moving forward to complete the
Bangkok Tenofovir Study.
The research team became aware during the first year of the
study that participant risk behavior differed from Vaccine Trial
participants, suggesting HIV incidence would be lower than
expected. Here, we describe Bangkok Tenofovir Study recruit-
ment, screening, and enrollment, and contrast risk behavior of
Tenofovir Study participants with Vaccine Trial participants.
These findings led the research team to increase Bangkok
Tenofovir Study enrollment and change to an endpoint-driven
study design.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Community engagement
In preparation for the study, the research team met with IDUs
and representatives of organizations working with communities at
risk for HIV infection, to describe the project; distribute draft
protocols, consent forms, and education materials; and to gather
input for trial materials and procedures. Focus group discussions
were conducted to assess IDU willingness to join an HIV pre-
exposure prophylaxis study, understanding of clinical trial design
and procedures, and concerns about the use of tenofovir. A
community relations committee made up of at least one IDU from
each of the 17 BMA clinics was formed to provide ongoing
community input during the trial. The committee meets with the
research team every 2 months to discuss a broad range of issues
that impact IDUs, clinic staff, and the study.
Study setting and design
The study is being conducted at 17 BMA drug-treatment clinics
in the densely populated urban communities of Bangkok. The
clinics offer a range of services including HIV counseling and
testing, risk-reduction counseling, social and welfare services,
health education, primary medical care and referrals, methadone
treatment, condoms, and bleach to clean injection equipment with
demonstrations of appropriate use. These services are free of
charge. Thailand’s narcotics law prohibits the distribution of
needles to inject illicit drugs and needles are not provided in the
clinics; however, sterile needles and syringes are available to the
public over the counter at low cost (5 to 10 baht/0.12 to 0.25
USD) in pharmacies in Bangkok.
We based sample size calculations for the Tenofovir Study on
HIV incidence among IDUs in the 1999–2003 Vaccine Trial [23].
We estimated the efficacy of tenofovir to prevent HIV infection
was 67% and designed the study to have 80% power to
demonstrate at least 10% tenofovir efficacy with a one-sided type
1 error of 2.5%. In order to meet these criteria, we planned to
enroll 1600 participants and follow each participant for 12
months. During the first year of the Tenofovir Study we
discovered that participant reports of injecting and needle sharing
were less than observed in the Vaccine Trial, suggesting HIV
incidence would be lower than expected. Based on the original
Tenofovir Study design, a lower than expected HIV incidence
would have resulted in fewer endpoints (i.e., incident HIV
infections), a larger confidence interval around the efficacy
estimate, and a diminished likelihood the trial would determine
if daily oral tenofovir reduced the risk of HIV infection among
IDUs. In response, the Bangkok Tenofovir Study enrollment
target was increased from 1600 to 2400 and the study design was
changed from a defined 1-year follow-up period to an endpoint
(incident HIV infection)-driven design. These changes provide
82% power to demonstrate at least 10% tenofovir efficacy with a
one-sided type 1 error of 2.5%.
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The study protocol, informed consent documents, question-
naires, and education materials were reviewed and approved by
the BMA Ethical Review Committee, the Thailand Ministry of
Public Health Ethical Review Committee, and an Institutional
Review Board of the US Centers for Disease Control and
Prevention. The US Office for Human Research Protections
approved the follow-up of incarcerated participants.
An independent Data and Safety Monitoring Board conducts
annual safety reviews and one interim efficacy review. A clinical
research organization is employed to provide independent
oversight and assure compliance with international guidelines for
good clinical practice. Gilead (Gilead Sciences, Inc., Foster City,
California) provides tenofovir and placebo free of charge but has
not been involved in the design or conduct of the study, data
analysis, or the presentation of results.
Recruitment
Research staff placed posters and brochures describing the study
in the drug-treatment clinics, provided presentations about the
study at IDU drop-in centers, and were available at the clinics to
discuss the study with individuals interested in joining the trial.
Potential participants received an explanation of study objectives
and design, eligibility criteria, and study activities and procedures.
Eligibility evaluation
HIV-uninfected individuals aged 20 to 60 years who reported
injecting drugs during the previous 12 months were candidates for
the study. Table 1 lists eligibility criteria. We excluded people with
chronic HBV infection because of concerns about reactivation
(i.e., flares) of hepatic disease if use of tenofovir was stopped. HBV
vaccine is provided to enrolled participants who have no serologic
evidence of active or chronic Hepatitis B infection. We excluded
women who were pregnant or breast feeding and required women
to agree to abstain from sexual intercourse or use contraception
(i.e., oral, injection, or barrier) during the study because large well-
controlled studies of tenofovir had not been conducted among
pregnant or breast-feeding women. Contraceptives are provided to
participants free of charge.
Eligible volunteers completed a comprehension test to assess
understanding of key trial concepts. Volunteers meeting all
eligibility criteria were enrolled after providing written informed
consent.
Enrollment and randomization
Enrolled participants were randomly assigned in a 1:1 ratio to
receive daily oral tenofovir 300 mg or placebo. The randomiza-
tion list, created using a computerized random-number generator,
was shared with Gilead who prepared and labeled bottles with a
randomization number. When an eligible participant completed
the consent process, study staff assigned them the next sequential
randomization number. Participants, study staff, monitors, and
other staff involved in the trial are blinded to drug assignment for
the duration of the study.
Research staff collected baseline demographic and incarceration
information using interviewer-administered questionnaires. Par-
ticipants chose daily clinic visits with directly observed taking of
study drug (DOT) or monthly visits without DOT. At enrollment
and each monthly follow-up visit, participants are assessed for
adverse events, oral fluid is collected for HIV testing (OraQuick
Rapid HIV-1/2 Antibody Test, assembled in Thailand for
Orasure Technologies, Inc, Bethlehem, Pennsylvania) and urine
for pregnancy testing (OneStep urine test, ULTI Med Products,
Ahrensburg, Germany); adherence is assessed using an audio
computer-assisted self-interview (ACASI) and pill counts; and
adherence and HIV risk-reduction counseling are provided.
Reactive oral fluid HIV tests are confirmed using two different
enzyme-immunoassays on blood (EIA) (Genetic Systems HIV-1/
HIV-2 EIA, Washington, USA) and Western blot (Bio-Rad,
Redmond, Washington).
At enrollment, months 1, 2, 3, and every 3 months thereafter,
blood is collected for hematologic, hepatic, and renal safety
assessment. Participants complete a risk questionnaire assessing
drug use, incarceration, and sexual activity during the previous 3
months using an ACASI at enrollment and every 3 months
thereafter.
To compensate participants for their time, effort, and travel,
they receive 350 baht (,10 US dollars) for each monthly study
visit. Participants on the DOT schedule receive 70 baht (,2U S
dollars) each day they come to clinic and participants who come all
7 days in a week receive 350 baht for that week.
AIDSVAX B/E Vaccine Trial
The AIDSVAX B/E Vaccine Trial was a phase-3, randomized,
double-blind, placebo-controlled study conducted among IDUs at
BMA drug-treatment clinics during 1999–2003. HIV-uninfected
individuals aged 20 to 60 years who reported injecting drugs
during the previous 12 months were eligible for the trial. Pregnant
Table 1. Eligibility requirements for the Bangkok Tenofovir
Study.
In order to enroll potential participants must:
N Be 20 to 60 years-old
N Report injection drug use in the 12 months before screening
N Possess documentation of a Thai National Identification number
Have the following laboratory results from a blood or oral fluid specimen
collected in the 2 weeks before enrollment:
N A non-reactive HIV oral fluid test
N Hemoglobin $9 gm/dL
N Alanine aminotransferase (ALT) #102 U/L
N Aspartate aminotransferase (AST) #95 U/L
N Total bilirubin #1.5 mg/dL
N Amylase #144 U/L
N Phosphorus $2.2 mg/dL
N Negative hepatitis B surface antigen
N Calculated creatinine clearance $60 mL/min by the Cockcroft-Gault
formula where creatinine clearance in mL/min=Male: (1402age in
years)6(wt in kg)/726(serum creatinine in mg/dL)
Female: (1402age in years)6(wt in kg)60.85/726(serum creatininein mg/dL)
N Pass the Bangkok Tenofovir Study comprehension test
N Be willing and able to provide informed consent for study participation
N Beavailableandcommittedtodailyormonthlyfollow-upforatleast12months
In addition:
N Women must not be pregnant or breastfeeding and must be willing to
abstain from sexual intercourse or use contraception during the trial (i.e.,
oral, injection, or barrier)
N A volunteer may be excluded if s/he has a history of significant renal, liver, or
bonediseaseorotherclinical condition orprior therapythat,in the judgment
of the study physician, would make the subject unsuitable for the study
N A volunteer will be excluded if s/he is participating in another HIV
prevention, drug, or vaccine trial
doi:10.1371/journal.pone.0025127.t001
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chemistry or hematologic eligibility requirements. Detailed
descriptions of the study have been published [23,29–33]. Briefly,
2546 IDUs enrolled and were randomly assigned (1:1) to receive
either AIDSVAX B/E or placebo at months 0, 1, 6, 12, 18, 24,
and 30. An interviewer-administered questionnaire was used at
baseline and every 6 months to assess drug use, incarceration, and
sexual activity during the previous 6 months.
Statistical analysis
Vaccine Trial and Tenofovir Study participant enrollment
demographic and risk characteristics were compared using chi-
square for categorical variables and t-test or Wilcoxon rank sum
test for continuous variables. Adjusted odds ratios and 95%
confidence intervals (CI) were estimated using logistic regression;
factors significant (p,0.1) in univariate analyses were retained in
the multivariable model. In order to evaluate injection of heroin,
midazolam, and methamphetamine, we included these variables in
the multivariable model and did not include ‘injected any drugs’.
We used SAS version 9.2 (SAS Institute, Cary, North Carolina)
for statistical analyses.
Results
Baseline characteristics
From June 2005 through July 2010, 4094 people were evaluated
for enrollment (Figure 1). Their median age was 32 years (mean
33.3; range, 19–60), 82% were male and 11% were HIV infected.
HIV infection was the most common reason screened volunteers
were not able to enroll, followed by elevated AST or ALT (10%),
and current or chronic hepatitis B infection (6%).
Among the 2413 (59%) IDUs who enrolled, the median age was
31 years (mean 32.4; range, 20–59), 80% were male, 48% had a
primary school (grade 6) or less education, and 22% were in a
methadone treatment program (Table 2). Most participants
reported they had been incarcerated in the past: 1905 (79%) in
a police holding cell, 1403 (58%) in prison, and 1386 (57%) in
both. Participants reporting incarceration in police holding cells
had been incarcerated a median of 3 times (range, 1–60); in
prisons a median of 2 times (range, 1–20).
Baseline risk behavior data were available on 2405 (99.7%) of
enrolled participants. At enrollment, 1506 (63%) participants
reported they had injected drugs and 435 (18%) had shared
needles during the 3 months before enrollment. Among those who
injected, 801 (53%) injected methamphetamine, 558 (37%)
midazolam, 526 (35%) heroin, 124 (8%) other sedative-hypnotics,
and 55 (4%) other drugs. A substantial proportion of those who
injected drugs reported injecting more than one drug: 203 (14%)
injected methamphetamine and midazolam, 186 (12%) metham-
phetamine and heroin, 184 (12%) heroin and midazolam, and 69
(5%) heroin, methamphetamine, and midazolam.
Among the 610 (25%) participants who reported incarceration
during the 3 months before enrollment, 552 (90%) had been in a
police holding cell, 389 (64%) in prison, and 331 (54%) in both. Of
those who spent time in holding cells, 40 (7%) reported injecting
drugs and 36 (6%) reported sexual intercourse in the cells. Of
those who had been in prison, 33 (8%) reported injecting drugs
and 35 (9%) reported sexual intercourse in prison.
At enrollment, 682 (28%) participants reported they had not
had sexual intercourse with a same sex or opposite sex partner
during the previous 3 months; 1194 (50%) reported intercourse
with one partner; and 529 (22%) with more than one partner.
Among enrolled participants, 1044 (43%) reported sexual
intercourse with a partner with whom they lived, 78 (8%) using
a condom every time; 913 (38%) reported intercourse with at least
one casual (i.e., non-live-in) partner, 299 (37%) of the 806 male
participants used a condom every time. A data entry problem
limited assessment of condom use with casual partners to men.
Among the 1916 male participants who completed a risk
assessment at enrollment, 91 (5%) reported sexual intercourse
with at least one male partner and 44 (48%) of these men used a
condom every time. Most, 73 (80%), of these men also reported
sexual intercourse with women.
Bivariate and multivariable analyses comparing baseline charac-
teristics of Vaccine Trial and Tenofovir Study participants are
shown in Table 2. Tenofovir Study participants are considerably
less likely to inject drugs than Vaccine Trial participants (odds ratio
0.1, 95% CI 0.1-0.1, p,0.001). Multivariable analyses shows that
Tenofovir Study participants are more likely to be female and older
than Vaccine Trial participants (both, p#0.001). Tenofovir Study
Figure 1. Number of injection drug users screened and enrolled in the Bangkok Tenofovir Study in Bangkok, Thailand, 2005–2010.
doi:10.1371/journal.pone.0025127.g001
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have injected midazolam or methamphetamine than Vaccine Trial
participants (all, p,0.001). Tenofovir Study participants are less
likely to inject daily (p,0.001) or share needles (p=,0.001) but
more likely to report sexual intercourse with more than one partner
(p,0.001) than Vaccine Trial participants.
Discussion
The Bangkok Tenofovir Study, an ongoing HIV pre-exposure
prophylaxis trial among IDUs, has been successfully launched and
is fully enrolled. Participant reports of injection drug use and
needle sharing are significantly less than expected, suggesting HIV
incidence will be lower than incidence estimates used in the design
of the study. To improve the likelihood the trial achieves its
primary objective, to determine if daily oral tenofovir prevents
HIV infection, we increased the enrollment target from 1600 to
2400 and changed participant follow-up from a defined 1-year
follow-up period to an endpoint-driven design.
The lower level of risk behavior reported by Tenofovir Study
participants compared to Vaccine Trial participants is likely due to
several reasons. Risk-reduction counseling, methadone treatment,
Table 2. Results of bivariate and multivariate analysis comparing baseline demographic characteristics and risk activities reported
by injection drug users participating in the 1999–2003 AIDSVAX B/E Vaccine Trial and the ongoing Bangkok Tenofovir Study,
Thailand.
Vaccine Tenofovir
N=2546 N=2413 OR Adjusted OR
Variable No. (%) No. (%) (95% CI) P value (95% CI) P value
Sex Male 2377 (93.4) 1924 (79.7) 0.3 (0.2–0.3) ,0.001 0.4 (0.3–0.5) ,0.001
Female 169 (6.6) 489 (20.3) 1.0 1.0
Age (years) Mean 28.8 32.4 1.0 (1.0–1.1) ,0.001 1.1 (1.1–1.1) ,0.001
Education #Primary (year 6) 833 (32.7) 1154 (47.8) 1.9 (1.7–2.1) ,0.001 1.1 (0.9–1.3) 0.39
Secondary or more 1713 (67.3) 1259 (52.2) 1.0 1.0
Ever been in jail
(holding cell)
Yes 1943 (76.3) 1905 (79.0) 1.2 (1.0–1.3) 0.03 1.3 (1.0–1.8) 0.05
No 603 (23.7) 508 (21.0) 1.0 1.0
Ever been in prison Yes 1278 (50.2) 1403 (58.1) 1.4 (1.2–1.5) ,0.001 1.0 (0.8–1.2) 0.86
No 1268 (49.8) 1010 (41.9) 1.0 1.0
Reported risks* N=2546 N=2405
In methadone treatment Yes 2150 (84.4) 523 (21.8) 0.05 (0.04–0.06) ,0.001 0.1 (0.1–0.2) ,0.001
No 396 (15.6) 1882 (78.2) 1.0
Injected any drugs Yes 2389 (93.8) 1506 (62.6) 0.1 (0.1-0.1) ,0.001 Not included
No 157 (6.2) 899 (37.4) 1.0
Injected heroin Yes 2355 (92.5) 526 (21.9) 0.02 (0.02–0.03) ,0.001 0.05 (0.04–0.06) ,0.001
No 191 (7.5) 1879 (78.1) 1.0 1.0
Injected
methamphetamine
Yes 388 (15.2) 801 (33.3) 2.8 (2.4–3.2) ,0.001 2.7 (2.1–3.3) ,0.001
No 2158 (84.8) 1604 (66.7) 1.0 1.0
Injected midazolam Yes 236 (9.3) 558 (23.2) 3.0 (2.5–3.5) ,0.001 7.7 (5.9–10.0) ,0.001
No 2310 (90.7) 1847 (76.8) 1.0 1.0
Injection frequency Daily 936 (36.8) 204 (8.5) 0.2 (0.1–0.2) ,0.001 0.5 (0.4–0.7) ,0.001
,Daily 1610 (63.2) 2201 (91.5) 1.0 1.0
Shared needles Yes 790 (31.0) 435 (18.1) 0.5 (0.4–0.6) ,0.001 0.6 (0.5–0.8) ,0.001
No 1756 (69.0) 1970 (81.9) 1.0 1.0
In jail (police
holding cell)
Yes 360 (14.1) 552 (23.0) 1.8 (1.6–2.1) ,0.001 1.4 (1.0–1.8) 0.03
No 2186 (85.9) 1853 (77.0) 1.0
In prison Yes 188 (7.4) 389 (16.2) 2.4 (2.0–2.9) ,0.001 1.2 (0.8–1.6) 0.45
No 2358 (92.6) 2016 (83.8) 1.0
Sexual intercourse with
more than one partner
Yes 306 (12.0) 529 (22.0) 2.1 (1.8–2.4) ,0.001 2.0 (1.5–2.5) ,0.001
No 2240 (88.0) 1876 (78.0) 1.0 1.0
OR=odds ratio; CI=confidence interval.
*Vaccine Trial participants reported risks for the 6 months before enrollment while Tenofovir Study participants reported risks for the 3 months before enrollment.
doi:10.1371/journal.pone.0025127.t002
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have reduced risk behavior among IDUs attending the clinics.
Tenofovir Study eligibility requirements including blood chemistry
and hematologic assessments and the exclusion of individuals with
chronic hepatitis B infection may have led to the enrollment of a
population of participants who inject drugs and share needles less
frequently than participants in the Vaccine Trial. Changes in drugs
injected by Vaccine Trial participants were recognized during the
1999–2003 trial [32,33]. A decrease in heroin use, which is usually
injected, and more methamphetamine and midazolam use, which
canbetaken orallyorinhaled,maybecontributingtolowerlevels of
injection drug use and needle sharing. These changes coincided
with the Thai Government’s ‘War on Drugs’. The drug war was
launched in 2003 to decrease the supply of illicit drugs [34,35].
During 2003, the supply of heroin in Bangkok decreased and the
price increased four-fold from approximately 2500 to 10,000 Thai
baht (60 to 250 USD) per 1000 mg [32]. The price of methamp-
hetamine and midazolam increased as well, but remained more
affordable: methamphetamine 150–250 baht (4 to 6 USD) per
tablet and midazolam 40–60 baht (1 to 1.5 USD) per tablet. The
changes in drug use are likely due in part to the changes in drug
supply and cost.
It has taken 5 years to enroll 2413 IDUs in the Tenofovir Study
compared to 18 months to enroll 2546 IDUs in the Vaccine Trial.
More stringent Tenofovir Study inclusion criteria likely contrib-
uted to slower enrollment. There is also evidence that the number
of IDUs in Bangkok has decreased in recent years. Researchers
using capture-recapture methodology estimated there were 36,600
active opiate users in Bangkok in 1991 [36]. A population
assessment done in 2003 using respondent-driven sampling
methodology estimated there were 3595 IDUs in Bangkok [37].
Each methodology has limitations but the 10-fold difference
suggests the population of IDUs in Bangkok has decreased.
Incarceration is a common experience among IDUs in Bangkok
[29] with almost 80% of study participants reporting a history of
incarceration and 25% incarcerated during the 3 months before
enrollment. Previous studies have demonstrated an association
between incarceration and HIV infection [29,33,38] and infor-
mation about this association has been included in participant risk-
reduction counseling.
Tenofovir Study participants report modest levels of sexual
activity, with 78% reporting no sexual intercourse or intercourse
withonlyone partner duringthe 3 months beforeenrollment.Study
participants are, however, more likely to report sexual intercourse
than Vaccine Trial participants. This change in sexual behavior
may be related to decreasing heroin use and increasing metham-
phetamine use, warranting additional research [39,40]. Previous
studies among IDUs in Bangkok found no association between
sexual activity and HIV infection [22,33]. It will be important to
monitor participant sexual activity to see if this remains true.
There are a number of limitations to this analysis including the
use of self-reports. Self-reporting of stigmatized or illegal behavior
is problematic and under-reporting of these activities is possible
[41]. At baseline, Vaccine Trial participants reported risk behaviors
for the previous 6 months using a standardized interviewer-
administered questionnaire, while Tenofovir Study participants
reported risk behaviors for the previous 3 months using ACASI.
Studies suggest that ACASI provides an acceptable and more
accuratemethod ofcollectinghealthrisk behaviordatathan face-to-
face interviews [42–44]. Tenofovir Study participants may more
accurately report risk behaviors because of the shorter recall period
(3 months in the Tenofovir Study, 6 months in the Vaccine Trial)
and the use of ACASI. On the other hand, Vaccine Trial
participants had a longer time at risk and may have been more
willing to report risk behavior that took place more than 3 months
ago [42]. The use of different data collection tools and time frames
limits the comparability of risk behavior data from the two trials.
The Bangkok Tenofovir Study is fully enrolled. The Data Safety
and Monitoring Board has recommended trial continuation
following annual safety reviews and an interim efficacy review in
2009. Trial results demonstrating whether or not daily oral
tenofovir is safe to use among HIV-uninfected IDUs and if
tenofovir reduces the risk of HIV infection are expected in 2012.
Supporting Information
Checklist S1 CONSORT Checklist.
(DOC)
Protocol S1 Trial Protocol.
(DOC)
Acknowledgments
We thank the study participants, clinic staff, and the members of the
Bangkok Tenofovir Study Group.
The Bangkok Tenofovir Study Group
Principal Investigator: Kachit Choopanya; Clinic Coordination Team:
Suphak Vanichseni, Pravan Suntharasamai, Udomsak Sangkum, Boonrawd
Prasittipol; Bangkok Metropolitan Administration: Sithisat Chiamwongpaet,
Kraichak Kaewnil, Montira Thongsari, Manoj Leethochawalit, La-Ong
Srisuwanvilai, Rapeepan Anekvorapong, Kovit Yongvanitjit; Thailand
Ministry of Public Health: Somyot Kittimunkong; Thailand Ministry of
Public Health – US Centers for Disease Control and Prevention
Collaboration: Pasakorn Akarasewi, Benjamaporn Chaipung, Nartlada
Chantharojwong, Thitima Cherdtrakulkiat, Wannee Chonwattana, Rutt
Chuachoowong, Pitthaya Disprayoon, Timothy Holtz, Wanna Leelawiwat,
Robert Linkins, Michael Martin, Janet McNicholl, Philip Mock, Supawadee
Na-Pompet, Tanarak Plipat, Boonyos Raengsakulrach, Pairote Tararut,
Punneeporn Wasinrapee, Dararat Worrajittanon; US Centers for Disease
Control and Prevention: Roman Gvetadze, Lynn Paxton.
Author Contributions
Conceived and designed the experiments: MM SV PS US RC PAM ML
SC SK FvG JMM LP KC. Performed the experiments: MM SV PS US
RC FvG JMM KC. Analyzed the data: MM PAM PS. Contributed
reagents/materials/analysis tools: MM PAM ML SC KC. Wrote the
paper: MM SV PS US RC PAM ML SC SK FvG JMM LP KC.
References
1. Weniger BG, Limpakarnjanarat K, Ungchusak K, Thanprasertsuk S,
Choopanya K, et al. (1991) The epidemiology of HIV infection and AIDS in
Thailand. AIDS 5(Suppl. 2): S71–S85.
2. National AIDS Prevention and Alleviation Committee. UNGASS Country
Progress Report, Thailand. Thailand Ministry of Public Health, Depart-
ment of Disease Control. Available: http://data.unaids.org/pub/report/
2008/thailand_2008_country_progress_report_en.pdf Accessed 2011 May
26.
3. WHO. Epidemiological Fact Sheet on HIV and AIDS, Thailand, 2008 update.
Available: http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/
EFS2008_TH.pdf Accessed 2011 May 26.
4. De Clercq E, Sakuma T, Baba M, Pauwels R, Balzarini J, et al. (1987) Antiviral
activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines.
Antiviral Res 8: 261–272.
5. De Clercq E (2003) Clinical Potential of the Acyclic Nucleoside Phosphonates
Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus
Infections. Clin Microbiol Rev 16: 569–596.
6. Gallant JE, Deresinski S (2003) Tenofovir disoproxil fumarate. Clin Infect Dis
37: 944–950.
7. Gilead Sciences. Viread (tenofovir disoproxil fumarate) tablets [full prescribing
information] 2010. Foster CityCalifornia: Gilead Sciences, Available: http://
www.gilead.com/pdf/viread_pi.pdf. Accessed 2011 May 26.
Bangkok Tenofovir Study Participants
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e251278. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004)
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in
antiretroviral-naı ¨ve patients: a 3-year randomized trial. JAMA 292: 191–201.
9. Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, et al. (2006)
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and
efavirenz for HIV. N Engl J Med 354: 251–260.
10. Wainberg MA, Miller MD, Quan Y, Salomon H, Mulato AS, et al. (1999) In
vitro selection and characterization of HIV-1 with reduced susceptibility to
PMPA. Antivir Ther 4: 87–94.
11. Margot NA, Enejosa J, Cheng AK, Miller MD, McColl DJ, et al. (2009)
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-
naı ¨ve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz
compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
J Acquir Immune Defic Syndr 52: 209–21.
12. Kearney BP, Isaacson E, Satre J, Cheng AK (2003) Tenofovir DF and oral
contraceptives: Lack of a pharmacokinetic drug interaction [Abstract A-1618].
Intersci Conf Antimicrob Agents Chemother. Available: http://gateway.nlm.
nih.gov/MeetingAbstracts/ma?f=102265007.html. Accessed 2011 August 26.
13. Smith P, Kearney BP, Liaw S, Cloen D, Bullock JM, et al. (2004) Effect of
Tenofovir Disoproxil Fumarate on the Pharmacokinetics and Pharmacodynam-
ics of Total, R-, and S-Methadone. Pharmacotherapy 24: 970–977.
14. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, et al. (1995) Prevention of
SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine.
Science 270: 1197–1199.
1 5 .S u b b a r a oS ,O t t e nR A ,R a m o sA ,K i mC ,J a c k s o nE ,e ta l .( 2 0 0 6 )
Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protec-
tion against infection with simian human immunodeficiency virus in macaques
given multiple virus challenges. J Infect Dis 194: 904–911.
16. van Rompay KKA, Kearney BP, Sexton JJ, Colon R, Lawson JR, et al. (2006)
Evaluation of oral tenofovir disoproxil fumarate and topical tenofovir GS-7340
to protect infant macaques against repeated oral challenges with virulent simian
immunodeficiency virus. J Acquir Immune Defic Syndr 43: 6–14.
17. Garcı ´a-Lerma JG, Otten RA, Qari SH, Jackson E, Cong M-e, et al. (2008)
Prevention of Rectal SHIV Transmission in Macaques by Daily or Intermittent
Prophylaxis with Emtricitabine and Tenofovir. PLoS Med 5: e28. doi:10.1371/
journal.pmed.0050028.
18. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of
Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in
Pregnant HIV-1-Infected Women for Maternal Health and Interventions to
Reduce Perinatal HIV Transmission in the United States. May 24, 2010, 1–117.
Available: http://www.aidsinfo.nih.gov/contentfiles/PerinatalGL.pdf Accessed
2011 May 26.
19. Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, et al. (1997) A
case-control study of HIV seroconversion in health care workers after
percutaneous exposure. N Engl J Med 337: 1485–90.
20. CDC (2005) Updated U.S. Public Health Service Guidelines for the
Management of Occupational Exposures to HIV and Recommendations for
Postexposure Prophylaxis. MMWR 54(RR-9): 1–17.
21. Chuachoowong R, Martin M, Prasitiphol B, Vanichseni S, Suntharasamai P,
et al. (2008) Involving communities to inform an HIV prevention trial in
Bangkok [Abstract WEPE0262]. The 17th International AIDS Conference
2008, Mexico City. Available: http://www.aids2008.org/Pag/Abstracts.as-
px?AID=4362. Accessed 2011 May 26.
22. Vanichseni S, Kitayaporn D, Mastro TD, Mock PA, Raktham S, et al. (2001)
Continued high HIV-1 incidence in a vaccine trial preparatory cohort of
injection drug users in Bangkok, Thailand. AIDS 15: 397–405.
23. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006)
Randomized, double-blind, placebo-controlled efficacy trial of a bivalent
recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in
Bangkok, Thailand. J Infect Dis 194: 1661–71.
24. Karim QA, Karim SSA, Frohlich JA, Grobler AC, Baxter C, et al. (2010)
Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the
Prevention of HIV Infection in Women. Science 326: 1168–1174.
25. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, et al. (2010)
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex
with Men. NEJM 363: 2587–99.
26. FHI. FEM-PrEP Project. Available: http://www.fhi360.org/en/Research/
Projects/FEM-PrEP.htm. Accessed 2011 August 22.
27. Thigpen MC, Kebaabetswe PM, Smith DK, Segolodi TM, Soud FA, et al.
(2011) Daily oral antiretroviral use for the prevention of HIV infection in
heterosexually active young adults in Botswana: results from the TDF2 study.
[Abstract WELBC01]. The 6
th International AIDS Society Conference.
Available: http://pag.ias2011.org/abstracts.aspx?aid=4631. Accessed 2011
August 22.
28. Baeten J (2011) Antiretroviral Pre-Exposure Prophylaxis for HIV-1 prevention
among heterosexual African men and women: the Partners PrEP Study
[Abstract MOAX0106]. The 6
th International AIDS Society Conference.
Available: http://pag.ias2011.org/flash.aspx?pid=886. Accessed 2011 August
22.
29. Suntharasamai P, Martin M, Vanichseni S, van Griensven F, Mock PA, et al.
(2009) Factors associated with incarceration and incident HIV infection among
injection drug users participating in an HIV vaccine trial in Bangkok, Thailand,
1999–2003. Addiction 104: 235–242.
30. Vanichseni S, Tappero JW, Pitisuttithum P, Kitayaporn D, Mastro TD, et al.
(2004) Recruitment, screening and characteristics of injection drug users
participating in the AIDSVAXH B/E HIV vaccine trial, Bangkok, Thailand.
AIDS 18: 311–6.
31. van Griensven F, Keawkungwal J, Tappero JW, Sangkum U, Pitisuttithum P,
et al. (2004) Lack of increased HIV risk behavior among injection drug users
participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand.
AIDS 18: 295–301.
32. van Griensven F, Pitisuttithum P, Vanichseni S, Wichienkuer P, Tappero JW,
et al. (2005) Trends in the injection of midazolam and other drugs and needle
sharing among injection drug users enrolled in the AIDSVAX B/E HIV-1
vaccine trial in Bangkok, Thailand. Int J Drug Policy 16: 171–5.
33. Martin M, Vanichseni S, Suntharasamai P, Mock PA, van Griensven F, et al.
(2010) Drug use and the risk of HIV infection amongst injection drug users
participating in an HIV vaccine trial in Bangkok, 1999–2003. Int J Drug Policy
21: 296–301.
34. Human Rights Watch (2004) Not Enough Graves: The War on Drugs, HIV/
AIDS, and Violations of Human Rights. Human Rights Watch Report;
16:No. 8(C). Available: http://www.hrw.org/reports/2004/thailand0704/index.
htm Accessed 2011 May 26.
35. Vongchak T, Kawichai S, Sherman S, Celentano DD, Sirisanthana T, et al.
(2005) The influence of Thailand’s 2003 ‘war on drugs’ policy on self-reported
drug use among injection drug users in Chiang Mai, Thailand. International
Journal of Drug Policy 16: 115–121.
36. Mastro TD, Kitayapom D, Weniger BG, Vanichseni S, Laosunthom V, et al.
(1994) Estimating the Number of HIV-Infected Injection Drug Users in
Bangkok: A Capture-Recapture Method. Am J Public Health 84: 1094–1099.
37. Wattana W, van Griensven F, Rhucharoenpornpanich O, Manopaiboon C,
Thienkrua W, et al. (2007) Respondent-driven sampling to assess characteristics
and estimate the number of injection drug users in Bangkok, Thailand. Drug
and Alcohol Dependence 90: 228–233.
38. Choopanya K, Des Jarlais DC, Vanichseni S, Kitayaporn D, Mock PA, et al.
(2002) Incarceration and risk for HIV infection among injection drug users in
Bangkok. JAIDS 29: 86–94.
39. Mirin SM, Meyer RE, Mendelson JH, Ellingboe J (1980) Opiate use and sexual
function. Am J Psychiatry 137: 909–15.
40. Daniell HW (2002) Narcotic-induced hypogonadism during therapy for heroin
addiction. J Addict Dis 21: 47–53.
41. Konings E, Bantebya G, Carae ¨l M, Bagenda D, Mertens T (1995) Validating
population surveys for the measurement of HIV/STD prevention indicators.
AIDS 9: 375–82.
42. van Griensven F, Naorat S, Kilmarx PH, Jeeyapant S, Manopaiboon C, et al.
(2006) Palmtop-assisted Self-Interviewing for the Collection of Sensitive
Behavioral Data: Randomized Trial with Drug Use Urine Testing.
Am J Epidemiol 163: 271–8.
43. Des Jarlais DC, Paone D, Milliken J, Turner CF, Miller H, et al. (1999) Audio-
computer interviewing to measure risk behaviour for HIV among injecting drug
users: a quasi-randomised trial. Lancet 353: 1657–61.
44. Metzger DS, Koblin B, Turner C, Navaline H, Valenti F, et al. (2000)
Randomized controlled trial of audio computer-assisted self-interviewing: utility
and acceptability in longitudinal studies. Am J Epidemiol 152: 99–106.
Bangkok Tenofovir Study Participants
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e25127